ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that the Data Monitoring Committee (DMC) has completed its planned safety data review of the second dose cohort of its clinical trial of ASLAN004 in moderate to severe atopic dermatitis (AD) patients. ASLAN004 was found to be well tolerated at 400mg and the DMC has recommended that the multiple ascending dose (MAD) clinical study continue as planned.
For more information, please refer to the English press release.